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Personalized ctDNA micro‑panels
can monitor and predict
clinical outcomes for patients
with triple‑negative breast cancer
Erica K. Barnell1,2, Bryan Fisk1,2, Zachary L. Skidmore1,2, Kelsy C. Cotto1,2, Anamika Basu1,2,
Aparna Anand1,2, Megan M. Richters1,2, Jingqin Luo3,4, Catrina Fronick2, Meenakshi Anurag5,
Robert Fulton2, Matthew J. Ellis5, Obi L. Griffith1,2,3,6*, Malachi Griffith1,2,3,6* &
Foluso O. Ademuyiwa1,3*
Circulating tumor DNA (ctDNA) in peripheral blood has been used to predict prognosis and therapeutic
response for triple-negative breast cancer (TNBC) patients. However, previous approaches typically
use large comprehensive panels of genes commonly mutated across all breast cancers. Given the
reduction in sequencing costs and decreased turnaround times associated with panel generation,
the objective of this study was to assess the use of custom micro-panels for tracking disease and
predicting clinical outcomes for patients with TNBC. Paired tumor-normal samples from patients with
TNBC were obtained at diagnosis (T0) and whole exome sequencing (WES) was performed to identify
somatic variants associated with individual tumors. Custom micro-panels of 4–6 variants were created
for each individual enrolled in the study. Peripheral blood was obtained at baseline, during Cycle 1 Day
3, at time of surgery, and in 3–6 month intervals after surgery to assess variant allele fraction (VAF) at
different timepoints during disease course. The VAF was compared to clinical outcomes to evaluate
the ability of custom micro-panels to predict pathological response, disease-free intervals, and patient
relapse. A cohort of 50 individuals were evaluated for up to 48 months post-diagnosis of TNBC. In
total, there were 33 patients who did not achieve pathological complete response (pCR) and seven
patients developed clinical relapse. For all patients who developed clinical relapse and had peripheral
blood obtained ≤ 6 months prior to relapse (n = 4), the custom ctDNA micro-panels identified molecular
relapse at an average of 4.3 months prior to clinical relapse. The custom ctDNA panel results were
moderately associated with pCR such that during disease monitoring, only 11% of patients with pCR
had a molecular relapse, whereas 47% of patients without pCR had a molecular relapse (Chi-Square;
p-value = 0.10). In this study, we show that a custom micro-panel of 4–6 markers can be effectively
used to predict outcomes and monitor remission for patients with TNBC. These custom micropanels show high sensitivity for detecting molecular relapse in advance of clinical relapse. The use
of these panels could improve patient outcomes through early detection of relapse with preemptive
intervention prior to symptom onset.
Neoadjuvant systemic therapy is widely used in patients with triple-negative breast cancer (TNBC). This
therapeutic approach permits assessment of clinically meaningful responses in vivo, which enables rapid
identification of effective drugs for tailoring adjuvant systemic therapy1. Approximately 30–65% of patients with
TNBC who receive neoadjuvant systemic therapy achieve a pathological complete response (pCR)2–7. Patients
who do not achieve a pCR tend to have a high rate of recurrence and poor overall s urvival8–10. The 3 year risk
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of distant recurrence for non-pCR patients is 27% versus 9% for those achieving p
 CR11. Three year event-free
survival after neoadjuvant chemotherapy is approximately 57%-68% in patients without pCR vs. 92%-94% in
patients with pCR6,8. The median survival, once TNBC has recurred, is only 18–28 months12,13. The inability
of chemotherapy to eradicate minimal residual disease is believed to be due to the escape of cells intrinsically
resistant to c hemotherapy14, which are not detectable with the current tools in routine clinical practice.
In this context, a liquid biopsy to measure circulating tumor DNA (ctDNA) offers a promising tool for
evaluating real-time response to chemotherapy. In advanced TNBC, next-generation sequencing of ctDNA shows
high concordance with mutations seen in tissue b
 iopsies15. ctDNA has also been evaluated as a promising tool
to predict outcomes in patients with breast c ancer16–22.
Most traditional sequencing approaches for ctDNA in patients with early-stage TNBC utilize universal panels
targeting recurrently mutated genes that are commonly observed in TNBC21,23. In these studies, panels do not
include somatic variants that are unique to each individual’s tumor. Since TNBC has high patient-to-patient
heterogeneity, such universal panels may miss patient-specific molecular changes. As such, we hypothesize that
custom micro-panels might improve sensitivity related to measuring clinical outcomes for patients in clinical
remission for breast cancer.
There have been a small cohort of studies that have evaluated custom micro-panels for this clinical utility. The
c-TRAK TN trial utilized custom ctDNA assays to track 1–2 patient-specific mutations to predict outcomes and
intervene with systemic therapy in a moderate-high risk cohort of patients with early-stage TNBC24. At a median
follow-up of 20.4 months, only 27.3% of patients had detectable ctDNA at 12 months, despite 72% having overt
metastatic disease on staging at time of ctDNA detection. These results suggest that custom assays composed of
multiple variants may improve the sensitivity of detecting minimal residual disease via ctDNA. Several additional
studies have correlated custom ctDNA expression with pathological complete response (pCR)22,25, and one study
showed correlation between detection of minimal residual disease (MRD) after curative surgery and disease
free survival26. Most commonly, these studies obtained ctDNA measurements at diagnosis and/or at 1-year
post surgery to compare presence of ctDNA biomarkers to ultimate disease status after a disease-free interval.
However, tracking custom ctDNA measurements during neoadjuvant therapy, at surgical resection, and at 3–6month intervals during disease-free intervals might provide additional insight into the prognosis for patients
with TNBC.
Herein, we report the results of a study of 50 patients in which we sought to determine if longitudinally
tracked ctDNA levels before, during, and after chemotherapy could predict clinical outcomes in TNBC patients
treated on an ongoing prospective trial (Fig. 1).

Methods

Patient clinical trial overview. This study enrolled patients into a phase II de-escalation clinical trial
designed to determine if a non-anthracycline regimen will achieve similar rates of pathological complete
responses to a standard anthracycline-containing regimen. Eligible patients treated on the parent clinical trial
included women at least 18 years old, with estrogen receptor (ER) negative (Allred score < 3 or less than 1%
positive staining cells in the invasive component of the tumor) and HER2 negative (0 or 1 + by IHC or FISH
negative) invasive breast c ancer27. Additional eligibility criteria included: Eastern Cooperative Oncology Group
Performance Status of 0 to 2, adequate organ and marrow function, and tumor size ≥ 2 cm in one dimension
by clinical or radiographic exam (WHO criteria)28. Patients with palpable lymph nodes were eligible regardless
of tumor size. Exclusion criteria included prior treatment of the current cancer, uncontrolled intercurrent
illness, bilateral or inflammatory cancer, pregnant/nursing, or prior sentinel lymph node biopsy. The study was
approved by the Institutional Review Board (IRB) at Washington University School of Medicine and followed
the Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was obtained from
each participant in the clinical trial. ClinicalTrials.gov identifier is NCT02124902.
All patients were treated with intravenous docetaxel 75 mg/m2 and carboplatin AUC 6 cycled every 21 days for
a total of six cycles. Definitive surgery was performed 3–5 weeks after completion of neoadjuvant chemotherapy.
Patients received adjuvant radiation when indicated, and adjuvant chemotherapy for patients without pCR was
left to the treating physician’s discretion.
Sample collection. When possible, tumor biopsies were obtained at baseline prior to chemotherapy (T0),
on Cycle 1 Day 3 of chemotherapy (T1- optional), and at the time of definitive surgery following neoadjuvant
chemotherapy in patients with residual disease (T2). Matched normal samples (T0-only) were obtained from
matched leukocyte germline DNA.
In addition, up to 50 mLs of peripheral blood were collected prospectively from patients at baseline (T0),
Cycle 1 Day 3 (T1), at time of definitive surgery (T2), and approximately every 6 months after surgical resection
of the breast cancer for a total of 5 years. If applicable, peripheral blood draws were also obtained at the time of
relapse (T4). ctDNA was extracted from plasma collected in Streck tubes.
Sample acquisition. Samples from 50 patients were used for this correlative study. A total of 378 blood
samples were obtained and sequenced (Fig. 2). All 50 patients had genomic WES completed for matched tumor/
normal pairs at Baseline (T0). Additionally, all 50 patients had ctDNA custom micro-panel sequencing performed
on peripheral blood for at least one timepoint during the disease course. ctDNA custom micro-panel sequencing
was performed for 46 patients at Baseline (T0), 39 patients at Cycle 1 Day 3, and 40 patients at Surgery. After
surgery, follow-up timepoints ranged from 3 to 48 months. More than half of all patients (n = 29 patients) had
ctDNA custom micro-panel sequencing performed at 6 months and the average patient had 5 timepoints with
ctDNA custom micro-panel sequencing (range = 1–10 timepoints). Additional genomic sequencing of tumor
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Figure 1.  Overview of the methods for sample collection and sequencing. (A) Tumor samples from biopsy
were obtained at baseline (T0). Blood samples were obtained at baseline (T0), Cycle 1 Day 3 (T1), at time
of surgery (T2), during follow-up (T3- every 3–6 month intervals for 5 years), and during relapse (T4). (B)
Baseline tumor samples were subjected to whole exome sequencing (WES) and variants were identified to build
a custom micro-panel. All blood samples (T0–T4) were assessed using the amplicon based custom micropanel. C. Sequencing was subjected to unique molecular identifier (UMI) based error correction. Variant allele
fractions (VAFs) were ascertained for baseline biopsies and ctDNA blood samples at all timepoints.
tissue and normal peripheral blood mononuclear cells (PBMCs) was performed at Baseline (T0), at Cycle 1 Day
3 (T1), and at Surgery (T2) for 16 patients based on sample availability. In total, 7 patients had clinical relapse
observed during the study, 4 of which had blood collected within 6 months of relapse.

Whole exome sequencing. Tumor DNA was extracted from fresh-frozen biopsies and matched germline

DNA from peripheral blood samples. WES data was generated for 50 unique baseline tumors and matched
blood DNA samples using the Illumina platform. Paired-end sequence libraries were constructed as described
previously29 with the following modifications. Samples were barcoded at the ligation step using Illumina unique
dual barcodes adapters (Cat# 20,022,370) and were amplified for 6–8 cycles using the Library Amplification
Ready-mix containing KAPA HiFi DNA Polymerase (Kapa Biosystems, Inc). For capture enrichment, libraries
were pooled in equimolar ratios in groups of 10 and were hybridized in solution to the HGSC VCRome 2.1
design30 Enriched libraries were sequenced on the NovaSeq 6000 instrument using the S4 reagent kit (300 cycles)
to generate 2 × 150 bp paired-end reads.

Somatic variant calling from exome data. Raw sequencing reads from tumor and normal tissue were

aligned to the human reference genome GRCh38 using Burrows-Wheeler Aligner31. The aligner output was
merged (if needed) and de-duplicated using Picard MarkDuplicates. A combination of four variant callers
(Mutect32, Varscan33, Strelka34, and Pindel35) was used to identify somatic variants by comparing normal and
tumor variant calls as previously described36. Variants were then annotated with the Variant Effect Predictor
(VEP) using Ensembl v95 annotations and filtered based on several criteria: previously known variants, variants
with high population-specific allele frequency, variants that are based on a high percentage of reads with 0
mapping quality, variants with low depth, and low confidence variants37.
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Figure 2.  For each of the 50 samples employed in the analysis, two sequencing platforms were employed: whole
exome sequencing (WES) and custom ctDNA micro-panel amplicon sequencing. All matched tumor/normal
genomics DNA samples underwent WES at baseline (T0). Based on sample availability, micro-panel sequencing
was employed on matched tumor/normal genomic DNA samples, tumor-only genomic DNA sample, normalonly genomic DNA sample, or peripheral blood ctDNA samples obtained at various timepoints.

SWIFT custom amplicon assay development. After somatic variant calling, filtering, and manual
review of variants38 that were detected by exome sequencing (as described above) 4–6 variants were selected
for each patient to build a custom ctDNA micro-panel. Variants selected included any non-silent TP53 variant
observed supplemented by up to three additional variants with the highest variant allele fraction (VAF) (see
Supplementary Table 1).
ctDNA was isolated from 2 to 10 mL of plasma utilizing two different protocols: (a) the Maxwell RCS
instrument and Maxwell RSC ctDNA Plasma Kit (Promega) or (b) QIAamp MinElute ctDNA Mini kit (Qiagen).
The isolated ctDNA was dried down to 14 uL prior to a PCR-based enrichment strategy utilizing a custom
designed Amplicon HS Panel from Swift Biosciences. Custom micro-panels designed at Swift Biosciences
included UMIs and were limited to ~ 100 amplicon primer pairs per pool and were separated into two batches.
Batch 1 was composed of 26 cases which included 154 ctDNA samples (multiple timepoints per case) and the
baseline tumor and normal genomic DNA, when available. Batch 2 was composed of 24 cases which included
109 ctDNA samples (multiple timepoints per case) and the baseline tumor and normal genomic DNA, when
available. The ctDNA input per enrichment ranged between 1 and 44 ng. Tumor and normal genomic DNA
input was consistently 25 ng. The amplicon libraries were constructed as outlined by the Custom Amplicon
HS library prep protocol and Target Amplification insert provided by Swift Biosciences, with the following
exceptions: automated libraries were generated on the Ep5075 instrument (Eppendorf); bead purification steps
were completed with AMPure XP beads at the same ratios outlined in the Swift HS Panel protocol; custom dual
unique sample indexes were added per library (TruSeq like primers with 10 bp unique dual indexes, diluted
to 2 uM per Swift recommendation); and the final index PCR step was increased to 9 cycles. Different sample
types (ctDNA, gDNA from Tumors, and gDNA from Normals) were processed on separate days to prevent any
cross-contamination.
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The concentration of the final libraries was determined by qPCR (KAPA Biosystems/Roche). 2 × 150 bp
paired-end sequence data was generated on the NovaSeq 6000 S4 flow cell targeting ~ 6 million read pairs per
library. A unique UMI was assigned to each original single-strand template, corresponding to the first 10 bp of
read 2.

SWIFT sequence data alignment,UMI consensus determination, andVAF estimation. Processing

of ultra high depth amplicon sequence data from the SWIFT targeted assay was performed using a computational
pipeline that employs custom-built tools created at Washington University. Sequencer generated FASTQ files
were first demultiplexed and aligned to the reference genome (GRCh38). During this process, UMI sequences
were added to the BAM file using fgbio ExtractUmisFromBam39. Once aligned, reads were grouped using fgbio
GroupReadsByUmi and collapsed into read families using fgbio CallMolecularConsensusReads. Consensus
reads were filtered using fgbio FilterConsensusReads if the read error rate exceeded 5% and individual bases in
the consensus were filtered if the error rate exceeded 10%. If the read comprised greater than 50% no calls from
this base filtering, then the read was removed. Quality control (QC) measures included requiring a minimum
mean unique coverage of 500 reads. Variant allele frequencies (VAFs) were obtained for each somatic variant
position (previously detected by exome sequencing as described above) using Bam-readcount40.

Germline variant calling for BRCA Variants. Exome sequencing data from baseline normal samples was
used to assess samples for pathogenic or likely pathogenic germline gene mutations for breast cancer. Samples
were analyzed with germline CWL pipelines developed at Washington University and variants were called across
all genes. BRCA1 and BRCA2 variants were identified and annotated using the Variant Effect Predictor tool
(VEP)37. Variants were manually reviewed using a previously defined standard operating procedure38. Variant
pathogenicity was evaluated using the ClinVar Allele Registry41 and the BRCA Exchange42. BRCA status observed
on (WES) was compared with previously performed molecular tests to ensure the accuracy of the pipeline.
Statistics. The overall sample size for the study (n = 50) was driven by the need to obtain enough relapse
cases so that the lower 95% exact confidence limit for the sensitivity was at least 50%. Assuming a relapse rate
of 15–20%, we anticipated 10 patients eligible for the primary analysis. At an observed sensitivity of 90% (9
of 10 samples detected using molecular analysis), the lower bound of the 95% confidence interval was 55%.
Reduced relapse rate in our population (n = 7), and incomplete compliance with blood collection process (n = 25)
prevented statistical endpoints from being significant. All data reported in this study should be considered
observational. To assess differences between ctDNA positivity and pathological complete response (pCR), a
Chi-Square test was used.

Results

Clinical Data.

Primary clinical outcome results from the phase II parent clinical trial have been published27.
For the translational cohort in which ctDNA was surveyed longitudinally, the average age was 52 years (range
25–74), 32% were African-American, and 84% had clinical stage II disease. Table 1 details the patient and tumor
characteristics for this translational cohort. Seven patients (14%) developed recurrent disease, and 5 patients
(10%) had died at the time of report generation.

Whole exome sequencing for custom ctDNA micro‑panel development. Whole exome
sequencing was performed on baseline normal and paired tumor samples as well as additional timepoints where
available (see Methods). Across all targeted exon positions, the median coverage of normal and tumor samples
was 79 bases (range = 44–146 bases) and 73 bases (range = 18–137 bases), respectively. A median of 77.5 somatic
variants (range of 1–1970) was identified across all tumors (Fig. 3). In total, 7513 variants were identified. TP53
mutations were identified in 86% of tumors (n = 43 patients). Two samples (NTN069 and NTN056) had a high
mutational burden (> 750 variants); neither patient had an observed BRCA1 / BRCA2 variant (Table 1). WES
variants from Baseline (T0) samples (matched tumor/normal tissue biopsies) were used to develop SWIFT
custom micro-panels for individual patients. In total, 208 variants were selected across all 50 patients for
developing the custom ctDNA micro panels (Supplementary Table 1).
There were 8 samples that had WES of the tumor tissue and custom ctDNA micro-panel sequencing of the
peripheral blood at baseline (T0). Across the 33 detectable variants in the 8 samples, 82% (n = 27 variants) were
detectable in both the tissue and the peripheral blood, which confirmed accuracy and concordance between
tumor sequencing and peripheral blood sequencing. The mean VAF of variants in the baseline tumor tissue was
32.9% whereas the mean VAF of variants in the peripheral blood was 0.33%.
ctDNA monitoring and clinical outcomes. In total, 208 unique variants were targeted for all 50 unique

patient samples (Supplementary Table 1). On average, 4 amplicons were designed for each sample (range = 1–6
amplicons). Of the 50 patients analyzed in this study, 7 patients had a clinical relapse reported during the disease
monitoring period. Of these, 4 had ctDNA sequencing performed within the 6 months of reported relapse
(Fig. 4). Three of the four patients showed molecular recurrence of the patient-specific amplicon signature prior
to reported clinical recurrence (Fig. 4A–C) and an additional patient showed persistent/residual disease at the
time of surgery prior to relapse at 2 months post-surgery (Fig. 4D). There were 3 additional patients with clinical
relapse, however their most recent ctDNA timepoint was greater than 6 months prior to relapse, precluding
the ability of the ctDNA micro-panel in predicting clinical relapse (Supplementary Fig. 1). These data indicate
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ID

Age

Race

BRCAWES
BRCAPCR Analysis Analysis*

Stage at Dx

Nodes at Dx

Grade at Dx

pCR

Recurrence

Duration of Follow
up (months)

NTN005

50

Caucasian

Negative

Negative

2

Yes

2

No

No

60

NTN006

44

African American

Negative

Negative

3

Yes

3

No

No

67

NTN007

54

African American

Negative

Negative

2

Yes

3

Yes

No

64

NTN009

57

African American

Negative

Negative

2

No

3

No

No

39

NTN012

49

Caucasian

BRCA1

BRCA1

2

No

3

No

No

43

NTN013

64

African American

Negative

Negative

2

No

3

No

No

64

NTN014

50

Caucasian

Unknown

Negative

2

Yes

3

Yes

No

64

NTN016

57

Caucasian

Unknown

Negative

2

Yes

3

Yes

No

64

NTN017

54

Caucasian

Negative

Negative

2

No

3

No

No

64

NTN018

28

Caucasian

Negative

Negative

2

No

3

Yes

No

29

NTN020

74

Caucasian

Unknown

Negative

3

Yes

3

No

No

61

NTN021

56

African American

Unknown

Negative

2

No

3

No

Yes

48

NTN022

66

Caucasian

Unknown

Negative

3

Yes

3

No

No

39

NTN023

31

Caucasian

Negative

Negative

3

Yes

3

Yes

No

63

NTN024

74

Caucasian

Unknown

Negative

2

No

2

Yes

No

49

NTN025

53

African American

Negative

Negative

2

No

3

Yes

No

62

NTN028

40

Caucasian

Negative

Negative

3

Yes

3

No

Yes

39

NTN029

50

African American

Negative

Negative

2

Yes

3

No

No

61

NTN031

46

Caucasian

Negative

Negative

3

Yes

3

Yes

No

56

NTN033

31

Caucasian

Negative

Negative

2

Yes

3

No

Yes

24

NTN034

27

African American

BRCA1

BRCA1

2

No

3

Yes

No

29

NTN037

58

African American

Unknown

Negative

2

No

3

Yes

No

44

NTN038

42

Caucasian

Unknown

Negative

2

Yes

3

No

No

53

NTN039

51

African American

Negative

Negative

2

No

3

Yes

No

28

NTN040

51

Caucasian

Unknown

Negative

2

Yes

2

No

No

54

NTN042

65

African American

Negative

Negative

2

No

2

No

No

53

NTN044

64

Caucasian

Unknown

Negative

2

No

3

Yes

No

54

NTN046

49

Caucasian

Unknown

Negative

2

Yes

3

Yes

No

42

NTN049

46

Caucasian

Negative

Negative

2

Yes

2

No

No

50

NTN050

59

Caucasian

Negative

Negative

2

No

3

Yes

No

41

NTN052

63

Caucasian

Unknown

Negative

2

No

3

No

No

43

NTN056

54

Caucasian

Unknown

Negative

2

Yes

2

No

No

41

NTN057

53

Caucasian

Negative

Negative

2

No

3

No

No

47

NTN058

40

Caucasian

Negative

Negative

2

No

3

Yes

Yes

19

NTN060

25

Caucasian

Unknown

Negative

2

No

3

Yes

No

20

NTN062

64

African American

Unknown

Negative

2

Yes

3

No

No

28

NTN063

59

Caucasian

Negative

Negative

2

No

3

No

No

47

NTN069

55

Caucasian

Unknown

Negative

2

No

3

No

No

45

NTN074

70

Caucasian

Unknown

Negative

2

No

3

No

No

43

NTN076

28

African American

BRCA1

BRCA1

2

Yes

3

No

Yes

41

NTN080

34

Other

Negative

Negative

3

Yes

3

No

No

27

NTN081

56

Caucasian

Unknown

Negative

3

Yes

3

No

No

38

NTN083

30

Caucasian

Negative

Negative

2

No

3

Yes

No

37

NTN084

44

Caucasian

Negative

Negative

2

Yes

3

No

No

35

NTN085

48

Caucasian

Negative

Negative

2

No

3

No

Yes

35

NTN087

59

African American

Unknown

Negative

2

No

3

No

No

33

NTN089

69

Caucasian

Unknown

Negative

2

No

3

No

No

35

NTN090

71

African American

Unknown

Negative

2

No

3

No

Yes

30

NTN091

60

African American

Negative

Negative

2

Yes

3

No

No

27

NTN092

67

Caucasian

Unknown

Negative

2

No

3

No

No

19

Table 1.  Overview of patients and demographic information. *Whole exome sequencing (WES) analysis
on BRCA1/BRCA2 variant status is provided in Supplementary Table 2. Dx = diagnosis; pCR = pathological
complete response.
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Figure 3.  Waterfall plot of Baseline (T0) WES for tumor/matched normal genomic DNA. Each column
represents a sample that had whole exome sequencing. Rows represent mutated genes across all samples.
Variants predicted to have no impact on protein sequence are only shown in the top mutation frequency panel.
The left panel indicates the number of samples containing a mutation in the indicated gene, whereby the top 30
genes are displayed. The top panel indicates the total number of variants observed in each sample, even those
that are not shown in the waterfall plot.
that molecular relapse using the ctDNA micro-panel detected 4 of 4 patients in advance of clinical relapse if the
ctDNA micro-panel was performed within 6 months of clinical relapse.
Twenty-one patients did not develop clinical relapse during monitoring. Of these, 17 showed molecular
remission using the custom ctDNA micro-panel (Fig. 5, Supplementary Fig. 2). There were 4 patients who
demonstrated potential molecular relapse with no clinical relapse (Supplementary Fig. 3). One patient
(NTN0022) was lost to follow up within the conceivable timeframe of clinical relapse. The other 3 patients were
followed for at least 22 months post potential molecular relapse. Given that only one of the 3–4 variants for each
sample was detected as positive at the molecular level, it is possible that these samples were potentially false
positives. These patients are still being followed on the parent trial.
Of the 50 patients analyzed in this study, 22 were not discussed above: 16 patients had either no baseline
data, no data post-surgery, or insufficient biomarkers for assessment (Supplementary Fig. 4); 4 patients had a
ctDNA VAF of baseline variants at < 0.05% (Supplementary Fig. 5A), and 2 patients had variants that appeared
to be germline variants (e.g., detected at 100% VAF in peripheral blood) (Supplementary Fig. 5B).

Association between ctDNA positivity and pCR. Of the 50 patients analyzed in this study, 25 were
eligible for evaluating ctDNA as a biomarker of recurrence (Figs. 4, 5, Supplementary Fig. 2–3). A sample was
determined to have a positive ctDNA result if any variant in the custom ctDNA micro-panel had a VAF > 0.005%.
Each patient was assessed at each timepoint to determine positivity. Of the 8 individuals with pCR, only 1 patient
(12.5%) showed a positive ctDNA result at any timepoint during remission. Conversely, of the 17 individuals
without pCR, 8 patients (47%) showed a positive ctDNA result for at least one timepoint during remission. The
difference in the positivity rate between patients with pCR and patients without pCR showed non-significant but
trending correlation (p-value = 0.10; Chi-Square test) (Fig. 6).

Discussion

This observational study demonstrated that a custom micro-panel of 4–6 patient-specific variants applied to
ctDNA could be used to predict and monitor disease recurrence for patients with early-stage TNBC. Each variant
in this custom panel was unique to the individual, allowing for a precision approach for identifying molecular
relapse in advance of clinical relapse. Detection of patient-specific variants in ctDNA also showed trending
correlation with failure to achieve pCR, suggesting potential prognostic utility in patients with TNBC.
The use of a custom ctDNA micro-panel provided possible improvements relative to traditional universal
panels that have a set number of genes/loci for all tumors being evaluated. Specifically across the 50-patient
cohort, we identified over 200 variants derived from 177 unique genes, and 204 unique genomic loci. Use of
a universal panel might not cover useful variants that provide adequate sensitivity for detection of molecular
relapse during surveillance, which were potentially informative of clinical correlates such as molecular relapse
and association with pCR.
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Figure 4.  Patients who demonstrated molecular relapse in advance of clinical relapse. Each panel shows VAF
for patient-specific tumor markers across various timepoints. Clinical relapse is denoted with a vertical dotted
line. Low-performing probes (< 1,000X observed coverage) were not shown. (A) NTN021 showed no signal
at baseline or at C1D3. A spike in patient-specific VAFs occurred at 24 months, which was 7 months prior to
clinical relapse. (B) NTN028 showed evidence of patient-specific VAFs at baseline with an increase in VAF at
C1D3. The VAF of patient-specific markers were undetectable from 3 months until 12 months with a spike in
VAF at 18 months, which was 3 months prior to clinical relapse. (C) NTN033 showed patient-specific VAFs at
baseline and at C1D3. Patient-specific markers were undetectable at time of surgery and at 6 months. Patientspecific markers spiked at 12 months, which was 5 months prior to clinical relapse. (D) NTN076 showed nonzero VAFs of patient-specific markers at the time of surgery with clinical relapse 2 months post-operation.
We demonstrated that assessment for residual disease by ctDNA is possible at approximately 6 month
intervals. While large comprehensive panels could be prohibitively expensive for assessing residual disease
at high-frequency intervals, smaller ctDNA micro-panels might be more feasible for confirming molecular
remission. Additionally, since the custom micro-panels are directly associated with the patient’s tumor, using
these patient-specific variants might improve sensitivity of molecular recurrence in advance of clinical relapse.
Custom variants identified for each individual’s tumor were not required to be known oncogenes or
tumor suppressors, however, many of the variants identified via WES (Fig. 3) and ctDNA (Fig. 4) had clinical
significance. TP53 contained the highest number of variants across all tumors, which has implications related
to prognosis in TNBC43. Additionally, putative driver variants in NF144,45 and RB146, have demonstrated clinical
relevance in previously reported breast cancer clinical trials. Interestingly, genes that are rarely mutated across all
TNBCs, including RECQL447 and TNC48, were observed in some patients in this study and have potential clinical
significance related to prognosis and therapeutic response. Use of a custom panel to assess TNBC during disease
monitoring allows providers to assess and potentially select for clinically-relevant variants that are unique to an
individual’s tumors further providing advantages against a universal approach.
WES at baseline permitted confirmation of BRCA1 / BRCA2 variants observed in patients with TNBC. Three
patients had confirmed germline predisposition status and 22 patients with unknown status had no observed
pathogenic BRCA variants (Supplementary Table 2). The use of baseline WES panels could serve as a replacement
for germline predisposition testing while also providing the custom targets for disease monitoring post-resection.
This would also mitigate the need for multiple small panels for germline predisposition testing.
There were some limitations to this study. First, there were several patients who were lost to follow-up (see
Table 1). Additionally, half of the patients (n = 25) had no peripheral blood for ctDNA isolation collected at
timepoints that were imperative for analysis, preventing them from being part of the primary analysis. For
example, 3 of the patients who developed clinical recurrence had a blood collection at more than 7 months
prior to recurrence, potentially preventing the ability to detect recurrence at the molecular level. Lack of study
compliance with required protocols greatly impacted the ability to detect significance for findings. Additionally,
peripheral blood collected post-relapse would have been important to demonstrate the VAF threshold for clinical
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Figure 5.  Monitoring clinical remission using a ctDNA molecular signature. Each panel shows patient-specific
VAFs across various timepoints. In total there were 17 patients that had both molecular and clinical remission.
A representative 4 patients are shown below. The remaining 13 patients are shown in Supplementary Fig. 2.

remission. Finally, it was observed that some probes did not generate sufficient coverage in peripheral blood
indicating the need for more than 1–2 variants in the micro-panel and rationale for why some other studies with
smaller panels demonstrated limited clinical utility49. We also recognize that post-surgery treatments were at
treating physician’s discretion and some of these treatments may have impacted detection of ctDNA.
Future studies are necessary to further demonstrate the use of personalized tumor micro-panels to predict
and monitor TNBC remission. Additional timepoints with more frequent intervals for ctDNA testing could be
utilized to further refine the sensitivity of the approach to detect molecular recurrence. Developing methods of
accurately identifying patients with TNBC who are at a high risk of relapse is an unmet medical need. If clinically
accurate biomarkers are developed, interventions that may change the natural history of relapsed TNBC could
also be developed.
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Figure 6.  Association between molecular relapse (tumor-specific VAF detection) and pathological Complete
Response (pCR). An algorithm was created to assess association between pCR and observed molecular relapse
using ctDNA VAF detection. The algorithm was considered positive if any of the variants in the custom micropanel had a VAF > 0.005%. Each patient was assessed at each timepoint to determine positivity. If the ctDNA
demonstrated molecular relapse, the timepoint was labeled in orange; ctDNA timepoints with no molecular
relapse were labeled in green. Abbreviations: R = Clinical Remission; T0 = Baseline; T1 = Cycle 1 Day 3 (C1D3).

Data availability

The datasets generated and/or analyzed during the current study are available in the dbGaP repository (accession:
phs002505).
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